MedPath

Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis

Not Applicable
Completed
Conditions
Breast Cancer
2D Mammography
3D Mammography
Registration Number
NCT01612650
Lead Sponsor
Centre Oscar Lambret
Brief Summary

This study aims to assess if using tomosynthesis for breast cancer surveillance will allow a significant decrease of ultrasound cliches (and radiation exposure)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
1069
Inclusion Criteria
  • woman with breast cancer histologically proven (group 1), on surveillance of a treated breast cancer (group 2) or diagnosis of an detected anomaly
  • age ≥ 40 years (group 1, group 2); age ≥ 50 years (group 3)
  • breast size suitable for detector size
  • possible prior mastectomy
  • security social covered
  • signed informed consent
Exclusion Criteria
  • breast implant
  • high genetic risk (mutation)
  • under justice measures
  • breast feeding or pregnant woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
determine the benefit of tomosynthesis for diagnosis30 months

number of avoided focused cliches and ultrasound, after tomosynthesis analysis

Secondary Outcome Measures
NameTimeMethod
number of additional cancer detected by tomosynthesis30 months

number of breast cancer detected through tomosynthesis

determine best incidence of realization30 months

face, medial side or oblique

measurement of breast irradiation30 months

comparison of tomosynthesis irradiation and focused cliches irradiation

evaluate non focused ultrasound residual place for 2 - 3 - 4 density breast30 months

Trial Locations

Locations (4)

Oscar Lambret Center

🇫🇷

Lille, France

Centre Hospitalier - Pavillon Paul Gelé

🇫🇷

Roubaix, France

Centre Hospitalier

🇫🇷

Valenciennes, France

Clinique des Dentellières

🇫🇷

Valenciennes, France

Oscar Lambret Center
🇫🇷Lille, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.